Lars Fogh Iversen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lars Fogh Iversen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Behrend F. Lundt
From the tOaProtein Chemistry, tOfDiabetes Biology, tOhNew Lead Discovery, tOjSignal Transduction, Novo Nordisk, DK-2880 Bagsvaerd, Denmark, tOdMed Chem Research I, tOgMed Chem Research IV, Novo Nordisk, DK-2760 Måløv Denmark, tOeDepartment of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark, and iOntogen Corporation, Carlsbad, California 92009
1 shared publicationClaus Bekker Jeppesen
From the tOaProtein Chemistry, tOfDiabetes Biology, tOhNew Lead Discovery, tOjSignal Transduction, Novo Nordisk, DK-2880 Bagsvaerd, Denmark, tOdMed Chem Research I, tOgMed Chem Research IV, Novo Nordisk, DK-2760 Måløv Denmark, tOeDepartment of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark, and iOntogen Corporation, Carlsbad, California 92009
1 shared publicationF. C. Wiberg
Novo Nordisk A/S, Novo Allé, DK‐2880 Bagsvaerd, Denmark
1 shared publication- Günther Herbert Johannes Peters
Technical University of Denmark
1 shared publication H. J. Flodgaard
Novo Nordisk A/S, Novo Allé, DK‐2880 Bagsvaerd, Denmark
1 shared publicationHenrik Sune Andersen
From the tOaProtein Chemistry, tOfDiabetes Biology, tOhNew Lead Discovery, tOjSignal Transduction, Novo Nordisk, DK-2880 Bagsvaerd, Denmark, tOdMed Chem Research I, tOgMed Chem Research IV, Novo Nordisk, DK-2760 Måløv Denmark, tOeDepartment of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark, and iOntogen Corporation, Carlsbad, California 92009
1 shared publication
Latest Publications
- Open Access
- 1 April 2000
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 275 (14) , 10300-10307
Structure-based Design of a Low Molecular Weight, Nonphosphorus, Nonpeptide, and Highly Selective Inhibitor of Protein-tyrosine Phosphatase 1B
- 1 April 2000
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 275 (14) , 10300-10307
Open AccessStructure-based Design of a Low Molecular Weight, Nonphosphorus, Nonpeptide, and Highly Selective Inhibitor of Protein-tyrosine Phosphatase 1B
- Open Access
- 1 January 1999
- Published by Wiley in Protein Science
- Vol. 8 (10) , 2019-2026
Structure and function of the N‐linked glycans of HBP/CAP37/azurocidin: Crystal structure determination and biological characterization of nonglycosylated HBP
The three N‐glycosylation sites of human heparin binding protein (HBP) have been mutated to produce a nonglycosylated HBP (ng‐HBP) mutant. ng‐HBP has been crystallized and tested for biological activity. Complete X‐ray data have been collected to 2.1 Å resolution, and the structure has been fully refined to an R‐factor of 18.4% (Rfree 27.7%). The ng‐HBP structure reveals that neither the secondary nor tertiary structure have changed due to the removal of the glycosylation, as compared to the previously determined glycosylated HBP structure. Although the primary events in N‐linked glycosylation occurs concomitant with polypeptide synthesis and therefore possesses the ability to influence early events in protein folding, we see no evidence of glycosylation influencing the structure of the protein. The root‐mean‐square deviation between the superimposed structures was 0.24 Å (on Cα atoms), and only minor local structural differences are observed. Also, the overall stability of the protein seems to be unaffected by glycosylation, as judged by the B‐factors derived from the two X‐ray structures. The flexibility of a glycan site may be determined by the local polypeptide sequence and structure rather than the glycan itself. The biological in vitro activity assay data show that ng‐HBP, contrary to glycosylated HBP, mediates only a very limited stimulation of the lipopolysaccharide induced cytokine release from human monocytes. In animal models of fecal peritonitis, glycosylated HBP treatment rescues mice from and an otherwise lethal injury. It appears that ng‐HBP have significant effect on survival, and it can be concluded that ng‐HBP can stimulate the host defence machinery albeit to a lesser extent than glycosylated HBP.
- 1 January 1999
- Published by Wiley in Protein Science
- Vol. 8 (10) , 2019-2026
Open AccessStructure and function of the N‐linked glycans of HBP/CAP37/azurocidin: Crystal structure determination and biological characterization of nonglycosylated HBP
The three N‐glycosylation sites of human heparin binding protein (HBP) have been mutated to produce a nonglycosylated HBP (ng‐HBP) mutant. ng‐HBP has been crystallized and tested for biological activity. Complete X‐ray data have been collected to 2.1 Å resolution, and the structure has been fully refined to an R‐factor of 18.4% (Rfree 27.7%). The ng‐HBP structure reveals that neither the secondary nor tertiary structure have changed due to the removal of the glycosylation, as compared to the previously determined glycosylated HBP structure. Although the primary events in N‐linked glycosylation occurs concomitant with polypeptide synthesis and therefore possesses the ability to influence early events in protein folding, we see no evidence of glycosylation influencing the structure of the protein. The root‐mean‐square deviation between the superimposed structures was 0.24 Å (on Cα atoms), and only minor local structural differences are observed. Also, the overall stability of the protein seems to be unaffected by glycosylation, as judged by the B‐factors derived from the two X‐ray structures. The flexibility of a glycan site may be determined by the local polypeptide sequence and structure rather than the glycan itself. The biological in vitro activity assay data show that ng‐HBP, contrary to glycosylated HBP, mediates only a very limited stimulation of the lipopolysaccharide induced cytokine release from human monocytes. In animal models of fecal peritonitis, glycosylated HBP treatment rescues mice from and an otherwise lethal injury. It appears that ng‐HBP have significant effect on survival, and it can be concluded that ng‐HBP can stimulate the host defence machinery albeit to a lesser extent than glycosylated HBP.